APAC Dendritic Cell Cancer Vaccines Market

APAC Dendritic Cell Cancer Vaccines Market Size (2023 to 2028):

The Dendritic Cell Cancer Vaccines Market size in the Asia Pacific is expected to grow at a promising rate between 2023 to 2028.

As per the National Institute of Cancer Prevention and Research, an estimated 2.25 million people in India are diagnosed with cancer, and 1,157,294 new cancer cases are being recorded annually. The growing cancer population, rising older people diagnosed with cancer, and increasing awareness among people over the treatment procedures are majorly influencing the industry growth. In addition to this, the government's growing measures to build awareness in people regarding the treatment and the availability of well-structured infrastructure are expected to drive the market further. The presence of many key players and huge investments made for the research in creating new drugs and vaccines are positive factors that boost business growth. Rising healthcare expenses, developments in advanced technologies, and betterments made for clinical trials' success rates help to have a hike in business growth.

However, adverse side-effects and some risks concerned with dendritic cells' applications are likely to curb market growth. The high cost of the treatment procedures is slowly hindering the growth rate of the market. 

This research report on the Asia Pacific Dendritic Cell Cancer Vaccines Market has been segmented and sub-segmented into the following categories:

By Product Type:

• CreaVax
• Sipuleucel-T (Provenge)

By End User:

• Pediatrics
• Adults

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Based on product type, Provenge was the first DC vaccine introduced in the market. So naturally, it follows that it is the market leader and is expected to remain so till the end of the forecast period. It treats melanoma, prostate cancer, etc. It was approved by the FDA nearly seven years ago.

Based on the region, the Asia Pacific will continue its high growth spurt till 2024. The booming economies of India and China are spearheading this spectacular growth. Countries like India and China are heading the immense growth in the dendritic cell cancer vaccine market. In India, around 4.5 lakhs people are suffering from the disease, and more than 7lakh new cases have been registering every year, and approximately 5,56,400 deaths occurred due to cancer. DENVAX is dendritic cell-based cancer immunotherapy for solid cancer in different stages of the disease. This aims the cancer cells importantly without threatening the healthy cells. It is used to control the development and slow down the spread of cancer and develop its life span. Adoption of sedentary lifestyles is expected to level up the demand of the market. The clinical trials of Phase II of dendritic cell therapy (DCT) have completely succeeded in India. Regular approvals by the U.S FDA for novel drugs and vaccines are responsible for the industry growth.

Some of the notable dominating the Asia Pacific Dendritic Cell Cancer Vaccines Market Profiled in the Report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation). Other players in the market include Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.